Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

He Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8679-7476; OpenAlex author ID A5103856807. Sources: OpenAlex.

Their work

Papers
5 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 5

  1. From static snapshots to spatial evolution: reconstructing the malignant progression from IPMN to invasive PDAC. First author DOI 10.1016/j.pan.2026.01.004↗
  2. Resveratrol inhibits pancreatic cancer progression via the ING5 signaling pathway. Last author DOI 10.1038/s41598-026-44216-x↗
  3. Resveratrol inhibits pancreatic cancer proliferation and metastasis by depleting senescent tumor-associated fibroblasts. Co-author DOI 10.4251/wjgo.v16.i9.3980↗
  4. Correction to: Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. Co-author DOI 10.1007/s00210-023-02499-1↗
  5. Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. Co-author DOI 10.1007/s00210-022-02203-9↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guotai Wang · 4 shared papers, 2022–2026 · strength 1.01
  2. Zheng Wang · 3 shared papers, 2022–2024 · strength 0.62
  3. Mingyang Liu · 1 shared paper, 2026 · strength 0.50
  4. Haoran Qi · 1 shared paper, 2026 · strength 0.50
  5. Qingyong Ma · 2 shared papers, 2022–2023 · strength 0.34
  6. Ying Xiao · 2 shared papers, 2022–2023 · strength 0.34
  7. Jingtao Gu · 2 shared papers, 2022–2023 · strength 0.34
  8. MA Qing-yong · 1 shared paper, 2024 · strength 0.28
  9. Zhenhua Ma · 1 shared paper, 2024 · strength 0.28
  10. Pengli Wang · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.